Monday, June 20, 1994
Amylin Pharmaceuticals Inc.
Analysts had mixed reactions to Amylin Pharmaceuticals Inc.'s Phase II data, but most maintained "buy" recommendations. The data showed significant smoothing of post-meal glucose, but failed to show inhibition of hypoglycemia in an insulin challenge. (For the data, see BioCentury, June 13, 1994)